ID

39086

Description

Valproate as First Line Therapy in Combination With Rituximab and CHOP in Diffuse Large B-cell Lymphoma; ODM derived from: https://clinicaltrials.gov/show/NCT01622439

Link

https://clinicaltrials.gov/show/NCT01622439

Keywords

Versions (1)
  1. 11/29/19 11/29/19 -
Copyright Holder

See clinicaltrials.gov

Uploaded on

November 29, 2019

DOI

To request one please log in.

License

Creative Commons BY 4.0
Model comments :

You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.

Back to model comments
Itemgroup comments for :

Item comments for :

In order to download data models you must be logged in. Please log in or register for free.

Eligibility Diffuse Large B-cell Lymphoma NCT01622439

English

Eligibility Diffuse Large B-cell Lymphoma NCT01622439

1 forms  
Inclusion Criteria
Description

Inclusion Criteria

Alias
UMLS CUI
C1512693
age 18-80 years
Description

Age

Data type

boolean

Alias
UMLS CUI [1]
C0001779
histologically confirmed (according to the who classification) diffuse large b-cell lymphoma stage ii-iv
Description

Diffuse Large B-Cell Lymphoma WHO tumor classification

Data type

boolean

Alias
UMLS CUI [1,1]
C0079744
UMLS CUI [1,2]
C1301142
no previous treatment for lymphoma. corticosteroids for alleviation of lymphoma associated symptoms are allowed
Description

Prior Therapy Absent Lymphoma | Adrenal Cortex Hormones Mitigation Intent allowed

Data type

boolean

Alias
UMLS CUI [1,1]
C1514463
UMLS CUI [1,2]
C0332197
UMLS CUI [1,3]
C0024299
UMLS CUI [2,1]
C0001617
UMLS CUI [2,2]
C1706602
UMLS CUI [2,3]
C0683607
who performance status 0-2
Description

WHO performance status scale

Data type

boolean

Alias
UMLS CUI [1]
C1298650
hiv negativity
Description

HIV negative

Data type

boolean

Alias
UMLS CUI [1]
C0481430
seronegativity for hcv, hbsag, anti-hbc, or other active infection uncontrolled by treatment
Description

Hepatitis C virus Seronegative | Hepatitis B Surface Antigens Seronegative | Anti-HBc antibody Seronegative | Infection Uncontrolled Seronegative

Data type

boolean

Alias
UMLS CUI [1,1]
C0220847
UMLS CUI [1,2]
C0521144
UMLS CUI [2,1]
C0019168
UMLS CUI [2,2]
C0521144
UMLS CUI [3,1]
C0948759
UMLS CUI [3,2]
C0521144
UMLS CUI [4,1]
C3714514
UMLS CUI [4,2]
C0205318
UMLS CUI [4,3]
C0521144
absence of psychiatric illness or condition which could interfere with the subjects ability understand the requirements of the study
Description

Mental disorders Absent | Interference Comprehension Study Protocol

Data type

boolean

Alias
UMLS CUI [1,1]
C0004936
UMLS CUI [1,2]
C0332197
UMLS CUI [2,1]
C0521102
UMLS CUI [2,2]
C0162340
UMLS CUI [2,3]
C2348563
absence of neurological or neuropsychiatric disorder, interfering with the requirements of the study
Description

Nervous system disorder Absent | Neuropsychiatric syndrome Absent | Interference Protocol Compliance

Data type

boolean

Alias
UMLS CUI [1,1]
C0027765
UMLS CUI [1,2]
C0332197
UMLS CUI [2,1]
C3203509
UMLS CUI [2,2]
C0332197
UMLS CUI [3,1]
C0521102
UMLS CUI [3,2]
C0525058
absence of hearing impairment > grade 2
Description

Absence Hearing impairment CTCAE Grades

Data type

boolean

Alias
UMLS CUI [1,1]
C0332197
UMLS CUI [1,2]
C1384666
UMLS CUI [1,3]
C1516728
absence of porphyria
Description

Porphyria Absent

Data type

boolean

Alias
UMLS CUI [1,1]
C3463940
UMLS CUI [1,2]
C0332197
in females: absence of pregnancy and lactation
Description

Gender | Pregnancy Absent | Breast Feeding Absent

Data type

boolean

Alias
UMLS CUI [1]
C0079399
UMLS CUI [2,1]
C0032961
UMLS CUI [2,2]
C0332197
UMLS CUI [3,1]
C0006147
UMLS CUI [3,2]
C0332197
all subjects must agree to abstain from donating blood while taking study drug therapy and for one week following discontinuation of study drug therapy
Description

Blood Donation Absent

Data type

boolean

Alias
UMLS CUI [1,1]
C0005794
UMLS CUI [1,2]
C0332197
all subjects must agree not to share study medication with another person, and to return all unused study drug to investigators
Description

Medication Sharing Absent | Investigational New Drugs Unused Return to Research Personnel

Data type

boolean

Alias
UMLS CUI [1,1]
C0013227
UMLS CUI [1,2]
C0237876
UMLS CUI [1,3]
C0332197
UMLS CUI [2,1]
C0013230
UMLS CUI [2,2]
C0445107
UMLS CUI [2,3]
C0332156
UMLS CUI [2,4]
C0035173
written informed concent according to ich/gcp and swedish regulations
Description

Informed Consent

Data type

boolean

Alias
UMLS CUI [1]
C0021430
Back to the top of the page

Similar models

Eligibility Diffuse Large B-cell Lymphoma NCT01622439

1 forms
Name
Type
Description | Question | Decode (Coded Value)
Data type
Alias
Item Group
C1512693 (UMLS CUI)
Age
Item
age 18-80 years
boolean
C0001779 (UMLS CUI [1])
Diffuse Large B-Cell Lymphoma WHO tumor classification
Item
histologically confirmed (according to the who classification) diffuse large b-cell lymphoma stage ii-iv
boolean
C0079744 (UMLS CUI [1,1])
C1301142 (UMLS CUI [1,2])
Prior Therapy Absent Lymphoma | Adrenal Cortex Hormones Mitigation Intent allowed
Item
no previous treatment for lymphoma. corticosteroids for alleviation of lymphoma associated symptoms are allowed
boolean
C1514463 (UMLS CUI [1,1])
C0332197 (UMLS CUI [1,2])
C0024299 (UMLS CUI [1,3])
C0001617 (UMLS CUI [2,1])
C1706602 (UMLS CUI [2,2])
C0683607 (UMLS CUI [2,3])
WHO performance status scale
Item
who performance status 0-2
boolean
C1298650 (UMLS CUI [1])
HIV negative
Item
hiv negativity
boolean
C0481430 (UMLS CUI [1])
Hepatitis C virus Seronegative | Hepatitis B Surface Antigens Seronegative | Anti-HBc antibody Seronegative | Infection Uncontrolled Seronegative
Item
seronegativity for hcv, hbsag, anti-hbc, or other active infection uncontrolled by treatment
boolean
C0220847 (UMLS CUI [1,1])
C0521144 (UMLS CUI [1,2])
C0019168 (UMLS CUI [2,1])
C0521144 (UMLS CUI [2,2])
C0948759 (UMLS CUI [3,1])
C0521144 (UMLS CUI [3,2])
C3714514 (UMLS CUI [4,1])
C0205318 (UMLS CUI [4,2])
C0521144 (UMLS CUI [4,3])
Mental disorders Absent | Interference Comprehension Study Protocol
Item
absence of psychiatric illness or condition which could interfere with the subjects ability understand the requirements of the study
boolean
C0004936 (UMLS CUI [1,1])
C0332197 (UMLS CUI [1,2])
C0521102 (UMLS CUI [2,1])
C0162340 (UMLS CUI [2,2])
C2348563 (UMLS CUI [2,3])
Nervous system disorder Absent | Neuropsychiatric syndrome Absent | Interference Protocol Compliance
Item
absence of neurological or neuropsychiatric disorder, interfering with the requirements of the study
boolean
C0027765 (UMLS CUI [1,1])
C0332197 (UMLS CUI [1,2])
C3203509 (UMLS CUI [2,1])
C0332197 (UMLS CUI [2,2])
C0521102 (UMLS CUI [3,1])
C0525058 (UMLS CUI [3,2])
Absence Hearing impairment CTCAE Grades
Item
absence of hearing impairment > grade 2
boolean
C0332197 (UMLS CUI [1,1])
C1384666 (UMLS CUI [1,2])
C1516728 (UMLS CUI [1,3])
Porphyria Absent
Item
absence of porphyria
boolean
C3463940 (UMLS CUI [1,1])
C0332197 (UMLS CUI [1,2])
Gender | Pregnancy Absent | Breast Feeding Absent
Item
in females: absence of pregnancy and lactation
boolean
C0079399 (UMLS CUI [1])
C0032961 (UMLS CUI [2,1])
C0332197 (UMLS CUI [2,2])
C0006147 (UMLS CUI [3,1])
C0332197 (UMLS CUI [3,2])
Blood Donation Absent
Item
all subjects must agree to abstain from donating blood while taking study drug therapy and for one week following discontinuation of study drug therapy
boolean
C0005794 (UMLS CUI [1,1])
C0332197 (UMLS CUI [1,2])
Medication Sharing Absent | Investigational New Drugs Unused Return to Research Personnel
Item
all subjects must agree not to share study medication with another person, and to return all unused study drug to investigators
boolean
C0013227 (UMLS CUI [1,1])
C0237876 (UMLS CUI [1,2])
C0332197 (UMLS CUI [1,3])
C0013230 (UMLS CUI [2,1])
C0445107 (UMLS CUI [2,2])
C0332156 (UMLS CUI [2,3])
C0035173 (UMLS CUI [2,4])
Informed Consent
Item
written informed concent according to ich/gcp and swedish regulations
boolean
C0021430 (UMLS CUI [1])
Back to the top of the page 

Contact

Please use this form for feedback, questions and suggestions for improvements.

Fields marked with * are required.

Help

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial